Synthetic Biologics Inc (SYN) Short Interest Update

Synthetic Biologics Inc (NYSEAMERICAN:SYN) was the target of a significant decrease in short interest in December. As of December 29th, there was short interest totalling 4,416,270 shares, a decrease of 9.7% from the December 15th total of 4,891,688 shares. Based on an average daily volume of 749,882 shares, the days-to-cover ratio is currently 5.9 days. Approximately 3.8% of the shares of the company are short sold.

Synthetic Biologics (SYN) opened at $0.53 on Thursday. The company has a market capitalization of $68.10, a price-to-earnings ratio of -2.41 and a beta of 1.13. Synthetic Biologics has a 12 month low of $0.41 and a 12 month high of $1.05.

Synthetic Biologics (NYSEAMERICAN:SYN) last issued its earnings results on Wednesday, November 1st. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.10).

A number of research analysts recently commented on the company. BidaskClub lowered Synthetic Biologics from a “hold” rating to a “sell” rating in a research note on Saturday, November 4th. Zacks Investment Research lowered Synthetic Biologics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 10th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the stock. Synthetic Biologics has an average rating of “Hold” and an average target price of $3.92.

WARNING: “Synthetic Biologics Inc (SYN) Short Interest Update” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at

Synthetic Biologics Company Profile

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.

Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with's FREE daily email newsletter.

Leave a Reply